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Introduction
The adenylyl cyclases (ADCY) are a ubiquitously expressed family of enzymes that catalyze the generation of cyclic adenosine monophosphate (cAMP) from adenosine triphosphate (ATP).
They regulate a broad range of cellular functions (Patel et al., 2001) and are critical effectors for a number of G protein-coupled receptors (GPCRs). Adenylyl cyclase activation has been suggested to be the rate-limiting step in the GPCR signalling cascade (Ostrom et al, 2000) . In vascular cells, activity of adenylyl cyclase regulates acute functional effects including vascular reactivity as well as cellular growth, hypertrophy, and apoptosis (Gros et al., 2006) . Furthermore, alterations in the regulation of adenylyl cyclase activity have been implicated in the pathogenesis of hypertension, heart failure, and diabetes (Matsumoto et al., 2005; Roth et al., 1999; Tepe and Liggett, 1999; Roth et al., 2002; Moxham and Malbon, 1996) .
Nine membrane-bound isoforms of adenylyl cyclase have been cloned-grouped into 3 major subfamilies comprising the following: Group 1: ADCY1, ADCY3, ADCY8, Group 2: ADCY2, ADCY4, ADCY7 and Group 3: ADCY5, ADCY6 (Patel, 2001) . Additionally, ADCY9
has been characterized as a distinct (and atypical) isoform (Sunahara and Taussig, 2002) with restricted expression, and a soluble adenylyl cyclase has been characterized that is the predominant form in mammalian sperm (Wuttke et al., 2001) . Each isoform has a specific pattern of tissue/organ distribution and a specific pattern of regulation by G proteins, calcium/calmodulin, and protein kinases (Sunahara and Taussig, 2002; Wuttke et al., 2001; Wang and Brown, 2004) .
Variability in cyclic AMP synthesis was thought to be determined predominantly either by the extent of adenylyl cyclase expression, by the specific characteristics of the GPCRs linked to enzyme activation, or by variation in the concentration of the "regulatory factors" (i.e., G This article has not been copyedited and formatted. The final version may differ from this version. -5 -proteins, protein kinases, ions) (Feldman and Gros, 1998) . The importance of "genetic" variability has been unappreciated; that is, the expression of genetic structural variants of the enzyme that differ by function and/or activity. However, recent studies by us and others have suggested that variability in the expression of ADCY genetic variants may be an important regulator of adenylyl cyclase-mediated responses (Small et al., 2003; Ikoma et al., 2003; Nordman et al., 2008) .
Several genetic variants have been described for a range of G proteins and GPCRs linked to adenylyl cyclase (Rana et al., 2001; Siffert, 2003) . Expression of these variants leads to alterations in receptor-mediated activation of adenylyl cyclase as well as alterations in downstream effector pathways. The identification of dysfunctional genetic variants of ADCY is presently limited to those in ADCY6, ADCY3 and ADCY9, of which the latter has a much more restricted distribution than other isoforms (Small et al., 2003) . A single nucleotide polymorphism (SNP) in intron 17 of gene encoding the very widely expressed ADCY6 isoform (Wang and Brown, 2004) was identified in a Japanese population (Nordman et al., 2008) . However, the impact of this variant on adenylyl cyclase function is currently unknown. In our initial studies, we discovered a relatively common (~7% in Caucasians) missense SNP in ADCY6, with the trivial name of ADCY6 A674S (Gros et al., 2005) . In a mammalian vascular cell system, specifically rat vascular smooth muscle cells transfected using adenoviral constructs, we have shown that expression of the ADCY6 A674S variant isoform resulted in enhanced adenylyl cyclase activity and function compared to expression of wild type ADCY6. Further in humans, expression of the ADCY6 A674S variant correlates with i) increased adenylyl cyclase enzymatic activity and ii) enhanced adenylyl cyclase-mediated vascular responses (Gros et al., 2007) .
This article has not been copyedited and formatted. The final version may differ from this version. Consequently, the present studies were performed to assess the association of the ADCY6 A674S variant with phenotypic characteristics within a large group of healthy, younger human subjects. Additionally, in a subset of these subjects we have examined the impact of expression of this genetic variant on hemodynamic responses both at rest and with exercise and orthostatic stress. Data to be presented demonstrate that carriers of the ADCY6 A674S genetic variant have increased blood pressure related to a hyperdynamic profile consistent with the effect of increased adenylyl cyclase function.
This article has not been copyedited and formatted. The final version may differ from this version. Of the 25 individuals that we identified as expressing the ADCY6 genetic variant we were able to recruit seven individuals (3 male) all of whom were heterozygotic carriers of ADCY6 A674S (hereafter referred to as the ADCY6 variant group) for more detailed analysis of cardiovascular responsiveness. Fourteen individuals (7 male) who did not express the genetic variant were recruited as a Control group. The mean +SEM ages of the control and ADCY6 variant groups were 26 ± 1 and 26 ± 1 years, respectively. By self-report, all participants were nonsmokers who were free of cardiovascular and neurological disease. Participants reported to the laboratory following at least a 3-h fast and having abstained from caffeine, alcohol, and exercise for a minimum of 12 hours. Preceding experimentation, participants were encouraged to maintain typical water consumption and sleeping behaviors. While the menstrual phase was not assessed, data between males and females displayed no perceptible difference and were, therefore, pooled. Informed consent was obtained for all analyses, with approval from the University of Western Ontario Research Ethics Review Board.
Measurements. During the initial screening, the five measurements of seated blood pressure and heart rate were averaged and recorded (BP Tru, VSM, Vancouver, British Columbia, Canada) . In the follow-up study of cardiovascular responsiveness, all measurements were performed with the participants in the supine position in a quiet, darkened room kept at a relatively constant temperature (21-23°C). Heart rate was recorded via a 3 lead ECG (Pilot 9200, Colin Medical Instruments, San Antonio, TX), blood pressure was measured continuously by finger photoplethysmography (Finapres 2300, Ohmeda, Englewood, CO) and validated intermittently via sphygmomanometry. Brachial artery mean blood velocity (4.7 MHz) and diameter (10 MHz imaging transducer) were assessed by pulsed-wave Doppler ultrasound (Echo Ultrasound Imaging; GE Vingmed System Five). Artery images were recorded on a S-VHS video cassette recorder (SVO-9500 MDP, Sony; Tokyo, Japan). Cardiac output (Q) was derived on a beat-by-beat basis from the transfer function of the finger pulsatile pressure waveform, as validated for these maneuvers (Shoemaker et al., 2007; Frances et al., 2008) . All analog data were sampled at 1000 Hz using a data-acquisition system (PowerLab, ADInstruments, Colorado Springs, CO). Cardiac output was normalized to body surface area (BSA) (Q c ) using the 
Flow mediated dilation:
Beyond adenylyl cyclase activation, vasodilator responses to exercise may also be mediated by endothelial factors (e.g. nitric oxide) in response to enhanced endothelial shear stress (Clifford and Hellsten, 2004) . This flow-mediated dilation (FMD) is predominantly mediated by endothelial responses. Thus, to determine whether any alterations seen in handgrip responses might be related to endothelial factors, a reactive hyperemia and FMD protocol was performed. While supine, a rapid inflation/deflation pneumatic cuff (Hokanson®, D.E. Hokanson Inc., Bellevue, WA) was placed around the right forearm immediately distal to the olecranon process to provide forearm ischemia and avoid excessive myogenic contributions to brachial artery dilation following ischemia (Betik et al., 2004; Corretti et al., 2002) . Ultrasound parameters were set to optimize longitudinal, B-mode images -10 -of the lumen/arterial wall interface. Specifically, central and forearm hemodynamics were recorded during 5 min of baseline, forearm cuff inflation to >200 mmHg for 5 min and then for 3 min after cuff deflation.
Lower body negative pressure: To determine whether any alterations in vasodilator responses between groups might be related to a generalized vascular "hyper-reactivity" characterized by both exaggerated vasodilator and vasoconstrictor responses we assessed blood flow and cardiac hemodynamic responses following lower body negative pressure (LBNP). The legs and hips were sealed in an air-tight container connected to a vacuum source (Kimmerly and Shoemaker, 2002) . Data collection for each test commenced following 5 min of undisturbed rest in the supine position. An initial 5 min baseline period was followed by 5 min of LBNP at -40 mm
Hg and, and finally, 5 min of rest at atmospheric pressure.
Blood processing and analysis: Blood samples were obtained from an antecubital fossa vein at baseline and during the LBNP protocol. A 3 ml sample of whole blood for determination of catecholamines was mixed with 75 µl of EGTA-glutathione anticoagulant and was centrifuged at 4°C for 15 min. A 6 ml sample of whole blood for determination of renin activity was collected in two 3 ml samples in 4 ml BD vacutainers, each containing 7.2 mg of EDTA and centrifuged at 4°C for 15 min.
Catecholamines were extracted from the plasma by adding acid-washed alumina and mixing by inversion. The pellet was washed with distilled water and the catecholamines were released into 0.1 M perchloric acid and separated by centrifugation. DNA analysis. Genomic DNA was extracted from whole blood as previously described (Gros et., 2005) . Briefly, genotyping of the ADCY6 A674S variant was performed using exon-specific DNA amplification followed by purification using shrimp alkaline phosphatase (Roche, Mannheim, Germany) and exonuclease I (ExoI; New England Biolabs, Mississauga, Canada) and capillary pheresis in an automated DNA sequencer as recently described (Cao and Hegele, 2003) .
Data analysis.
For the initial population screening, the statistical significance of differences in quantitative variables between control and ADCY6 variant groups was determined by student's ttest for unpaired data (Prism 4.0, GraphPad Software, San Diego, CA). In the sub-sample studied for cardiovascular responsiveness, the associations of genotype on baseline values and responsiveness (defined as the change in each variable from rest) were assessed using a mixed one-way repeated measures analysis of variance (ANOVA) (SAS® v.9.1, SAS Institute Inc., Cary, NC). Post hoc analysis of significant interactions was assessed using Bonferroni analysis.
Data are presented as mean ± standard error and statistical significance was assumed when p < 0.05.
This article has not been copyedited and formatted. The final version may differ from this version. A674S in a Caucasian population (Gros et al., 2007) .
ADCY6 variant associations:
Participants were classified according to g.2714G>T genotype
with the single 2714T/T homozygote added to the 2714G/T heterozygote group (S674 subjects), while the 2714G/G homozygotes formed the comparator group (A674 subjects). Seated systolic blood pressure was increased in ADCY6 S674 subjects compared to ADCY6 A674 subjects (p < 0.05; Table 1 ). Diastolic blood pressure also tended to be higher in the ADCY6 variant group, although this difference was of borderline significance (p = 0.05) ( Table 1) .
Waist circumference was reduced in the ADCY6 S674 variant group compared to the ADCY6 A674-expressing individuals (Controls) ( Baseline assessments were performed after approximately 20 minutes of quite supine rest. Systolic, mean arterial and diastolic blood pressures were all significantly increased in the ADCY6 variant group (Table 2) . Also, compared to the control group, those expressing the ADCY6 variant had increased mean heart rate and cardiac output (both p < 0.05).
Under baseline conditions, plasma renin activity (PRA) was greater in the ADCY6 variant group (0.63 ± 0.11 ng/L/s) (p < 0.05) compared with control subjects (0.31 ± 0.11 ng/L/s). In contrast, baseline levels of plasma norepinephrine were similar between groups (Control = 1.28 ± 0.25 nmol/L, ADCY6 variant= 1.38 ± 0.24 nmol/L) (p > 0.1).
Handgrip exercise responses: Baseline measures of forearm blood flow (FBF) did not differ
between genotypic groups (p > 0.05). With exercise, FBF increased in both ADCY6 variant and control groups. However, compared with control subjects, the exercise-induced increase in FBF was almost 4 times greater in those expressing the ADCY6 variant (Fig. 1 , increased ~30% in the control subjects (p < 0.05) vs. ~120% in the ADCY6 variant group, p < 0.001).
Reactive hyperemia and flow mediated dilation (FMD):
To determine whether the increase in FBF seen following handgrip exercise was due to a generalized enhancement of vasodilatory responses-not specific to adenylyl cyclase mediated effects, we next assessed the (endothelialdependent) effect of reactive hyperemia on FBF. When compared to Control subjects, the ADCY6 variant group displayed no difference in baseline FBF (p = 0.181, Fig. 2 ) prior to the FMD procedure. Also, the initial hyperemic response to the deflation of the cuff was also 
Lower body negative pressure (LBNP):
During LBNP, both groups demonstrated reductions in FBF (p < 0.05; Fig. 3 A) . However, the forearm vascular response to LBNP was not greater in the ADCY6 variant group. In fact, the increase in TPR c in response to LBNP was greater in the control than the ADCY6 variant group (Fig. 3 B; p < 0.05). In contrast to the unchanged or blunted vascular responses to LBNP, the cardiac chronotropic responses to LBNP -mediated indirectly via baroreceptor unloading -were exaggerated in the ADCY6 variant group.
Compared to the insignificant increase in HR seen in controls following LBNP, in ADCY6 variants, HR was significantly increased (p < 0.05) (Fig. 4) . The increase in HR was 14 beats·min -1 greater in the ADCY6 variant group during LBNP vs. controls (p < 0.05) (Fig. 4) .
Notably, cardiac output in the ADCY6 variant group was significantly higher than controls both at rest and with LBNP (but not during the recovery phase, Fig. 5A ). However, the magnitude of fall in cardiac output during LBNP was similar in both groups (p > 0.05) (Fig. 5B ).
With LBNP, the increase in plasma norepinephrine with LBNP did not differ between -15 -
Discussion
Our recent studies had identified a relatively common amino acid variant of ADCY6, namely A674S (Gros et al., 2005; Gros et al., 2007) . Further, we have shown previously that this variant is hyperfunctional in vitro in the context of enzymatic activity as well as in the context of adenylyl cyclase-mediated vascular responses (Gros et al., 2007) . However, the significance of its expression in regards to phenotypic characteristics, as well as in vivo effects on responses to acute exercise, and vasoconstrictor stimuli were unknown. The present studies have confirmed that the ADCY6 A674S variant is present in ~7% of Caucasians, and further demonstrate that its expression is associated with increased blood pressure and hyperdynamic cardiovascular responses characterized by 1) increased cardiac output and heart rate 2) elevated plasma renin activity 3) a markedly greater vasodilator response to handgrip exercise and 4) augmented heart rate response to baroreceptor unloading (LBNP), without impact on reflex-mediated sympathetic forearm vasoconstriction. Together, the findings indicate that the expression of the ADCY6 A674S genetic variant leads to a hyperdynamic cardiovascular system both under baseline conditions and in response to stressors that activate adenylyl cyclase.
Determinants of increased blood pressure in subjects expressing the ADCY6 A674S genetic
variant. It could be reasonably argued that the major functional determinants of cAMP-mediated regulation of blood pressure relate to the effects of adenylyl cyclase activation on: i) cardiac contractility/heart rate, ii) the renin-angiotensin system (RAS) axis-via cAMP-mediated regulation of renin release iii) vascular reactivity-predominantly via vasodilator mechanisms. In -16 -conditions cardiac output was higher in the ADCY6 variant group. This effect seems to have been primarily related to the increased heart rate, since stroke volume did not differ significantly between groups. The observation that cardiac output was elevated, without appreciable reductions in afterload (higher systolic pressure and normal vascular resistance) in this group suggests that cardiac filling pressures were also sustained or elevated.
In regards to the potential effect of expression of the ADCY6 variant on vascular reactivity, total peripheral resistance was not reduced (nor was baseline FBF increased). Acutely, increased adenylyl cyclase activation (as would be seen with infusion of the non-selective beta adrenergic agonist, isoproterenol) is associated with decreased peripheral resistance-related to both direct and baroreflex-mediated responses. Notably, in our initial studies, subjects carrying the A674S ADCY6 genetic variant demonstrated enhanced adenylyl cyclase-mediated vasodilator responses as determined by the extent of isoproterenol-mediated vasorelaxation assessed by LVDT (Gros et al., 2007) . However, chronically, the direct effects of adenylyl cyclase activation on vascular reactivity would be expected to be modulated by its actions in regulating renin release. In the ADCY6 variant group, plasma renin activity was increased compared to the Control group.
Thus, the failure to detect a reduced total peripheral resistance in subjects expressing the ADCY6 variant might reflect the chronic effects of increased renin activity, leading to enhanced aldosterone-mediated effects on intravascular filling and/or increased ambient angiotensin IImediated effects. However, regardless of the countervailing balance of enhanced adenylyl cyclase-mediated vasodilation vs. enhanced adenylyl cyclase-mediated renin release on peripheral resistance, altogether, our findings support the hypothesis that the increased blood pressure in the ADCY6 variant group is primarily related to increased cardiac output and increased plasma renin activity. responses. Acute exercise causes rapid and large changes in muscle perfusion (Shoemaker et al., 1997a; Shoemaker et al., 1997b; Shoemaker et al., 1997c; Shoemaker et al., 1998) . Among the multiple mechanisms mediating this effect is the role of metabolic factors released by working muscles. The mediators of exercise hyperemia that are released from contracting skeletal muscle include adenosine and prostaglandins that act through GPCRs to affect intracellular calcium levels in vascular smooth muscle (Betik et al., 2004; Marshal, 2007) Interestingly, the ADCY6 variant group had ~4 cm decreased waist circumference reflecting a 10% decrease in abdominal girth, without a significant difference in body mass index. Waist circumference has been increasingly appreciated as a surrogate for abdominal fat and, more importantly, as a highly predictive risk factor for the development of the metabolic syndrome and, ultimately, atherosclerotic complications (Pouliot et al., 1994) . The observation that waist circumference, but not body mass index, was reduced in healthy, younger ADCY6
This article has not been copyedited and formatted. The final version may differ from this version. -18 -variant subjects suggests that the difference in waist circumference reflected a difference in abdominal fat, but not a difference in "whole-body" fat.
In summary, these data indicate that the expression of a novel, relatively common genetic variant of ADCY6 is associated with an increase in adenylyl cyclase function that parallels increased blood pressure and cardiac output and exaggerated adenylyl cyclasemediated responses to exercise as well as altered distribution of body fat. Whether these findings have implications in regards to the development of cardiovascular disease and/or complications related to visceral obesity-the metabolic syndrome and diabetes, remain to be determined. However, these studies do indicate that genetic regulation of GPCR-mediated adenylyl cyclase activation is an important determinant of human cardiovascular function.
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